FindTrial
Sign In

CAR-T cells

BIOLOGICAL19 trials

Sponsors

Affiliated Hospital to Academy of Military Medical Sciences, The Second Hospital of Nanjing Medical University, Guangzhou 8th People's Hospital, Benjamin Tomlinson, The First Affiliated Hospital of Guangdong Pharmaceutical University

Conditions

AMLAcute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, AdultB Cell LeukemiaB Cell LymphomaCAR-T Cell TherapyHIV-1HIV/AIDS

Early Phase 1

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies
RecruitingNCT04532203
Zhejiang UniversityAcute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
Start: 2020-11-01End: 2026-11-01Target: 72Updated: 2020-10-26

Phase 1

Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
NCT02186860
Affiliated Hospital to Academy of Military Medical SciencesAcute Lymphoblastic Leukemia
Start: 2016-07-31End: 2021-12-31Target: 5Updated: 2021-02-10
A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application
NCT02980315
The Second Hospital of Nanjing Medical UniversityNasopharyngeal Neoplasms
Start: 2016-11-30End: 2017-12-31Target: 20Updated: 2016-12-02
The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function
RecruitingNCT03240328
Guangzhou 8th People's HospitalHIV/AIDS
Start: 2017-10-04End: 2030-12-31Target: 40Updated: 2022-09-14
AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma
Active, not recruitingNCT03434769
Benjamin TomlinsonNon-Hodgkin Lymphoma
Start: 2018-07-09End: 2036-02-01Updated: 2026-02-27
Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC
NCT03525782
The First Affiliated Hospital of Guangdong Pharmaceutical UniversityLung Neoplasm Malignant, Non-small Cell Lung Cancer
Start: 2018-02-01End: 2022-01-31Target: 60Updated: 2018-05-16
Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies
NCT03881774
Henan Cancer HospitalB Cell Leukemia, B Cell Lymphoma, Refractory +1
Start: 2019-02-27End: 2022-01-31Target: 20Updated: 2019-03-21
Donor-derived CAR-T Cells in the Treatment of AML Patients
NCT04766840
Beijing Immunochina Medical Science & Technology Co., Ltd.AML
Start: 2021-03-01End: 2023-12-01Target: 9Updated: 2021-02-23
Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions
NCT04790747
Zhejiang UniversityHematological Malignancies
Start: 2021-03-31End: 2025-03-31Target: 50Updated: 2021-03-10
Third-Generation CAR-T-cell Therapy in Individuals With HIV-1 Infection
NCT04863066
Beijing 302 HospitalHIV-1
Start: 2021-05-01End: 2022-10-01Target: 8Updated: 2021-04-28
Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma
NCT05420493
Chongqing Precision Biotech Co., LtdNon Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
Start: 2021-09-06End: 2025-09-30Target: 54Updated: 2024-01-05
Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers
RecruitingNCT05779917
Second Affiliated Hospital of Guangzhou Medical UniversityCAR-T Cell Therapy, Mesothelin, Pancreas Cancer +1
Start: 2023-03-10End: 2036-03-10Target: 30Updated: 2024-06-25
Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)
RecruitingNCT06352281
920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaITP - Immune Thrombocytopenia
Start: 2024-02-01End: 2027-12-31Target: 10Updated: 2024-07-22
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
RecruitingNCT06429150
Shenzhen Geno-Immune Medical InstituteMultiple Myeloma, Plasmacytoma
Start: 2024-05-11End: 2027-12-31Target: 20Updated: 2024-06-10

Phase 2

To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)
RecruitingNCT06698484
National University of MalaysiaRelapsed/Refractory B- Cell Non-Hodgkin Lymphoma
Start: 2021-06-03End: 2026-06-02Target: 20Updated: 2024-11-21

Unknown Phase

A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies
NCT04008524
Institute of Hematology & Blood Diseases Hospital, ChinaRelapsed and Refractory Hematological Malignancies
Updated: 2025-08-06
CAR-T Cellular Therapy for B Cell Malignancies Involved in CNS
NCT04287309
Zhejiang UniversityHematological Malignancy
Start: 2020-02-28End: 2023-02-28Target: 20Updated: 2020-02-27
Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
RecruitingNCT06481241
Institute of Hematology & Blood Diseases Hospital, ChinaAcute Lymphoblastic Leukemia, Adult, Philadelphia Chromosome Negative ALL
Start: 2024-06-10End: 2028-06-01Target: 77Updated: 2026-03-02
Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
RecruitingNCT06481228
Institute of Hematology & Blood Diseases Hospital, ChinaAcute Lymphoblastic Leukemia, Adult, Philadelphia Positive Acute Lymphoblastic Leukemia
Start: 2024-06-04End: 2028-06-01Target: 82Updated: 2026-03-02

Related Papers

Front-line consolidation with CAR-t therapy in newly diagnosed adult ph-negative b-acute lymphoblastic leukemia: Results from a prospective, phase 2 study
Blood2025-11-03
Single CAR-t infusion during front-line consolidation induces deep and sustained remission in newly diagnosed adult ph+b- ALL: A prospective phase 2 study
Blood2025-11-03
Autologous CD19-directed CAR-T exhibit promising safety and efficacy in refractory primary immune thrombocytopenia
Blood2025-11-03
Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trial.
2025-03-041 citations
The Fourth Symposium of Grand Challenges on HIV (2023.12.28)
Infectious Diseases & Immunity2024-03-04
Redirector of Vaccine-induced Effector Responses (RoVER) for specific killing of cellular targets.
2023-09-042 citations
Circulating Tumor DNA Correlation with Lymphoma Response and Survival Outcomes at Multiple Time Points of Anti - CD19 CAR T Cell Therapy
Blood2022-11-154 citations
Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients
Nature Communications2021-12-1066 citations
Broadly neutralizing antibody–derived CAR T cells reduce viral reservoir in individuals infected with HIV-1
Journal of Clinical Investigation2021-08-1088 citations
Phase 1 trial of anti-CD19 chimeric antigen receptor T (CAR-T) cells with tumor necrosis alfa receptor superfamily 19 (TNFRSF19) transmembrane domain.
Journal of Clinical Oncology2019-05-203 citations
Anti-MUC1 CAR-T cells combined with PD-1 knockout engineered T cells for patients with non-small cell lung cancer (NSCLC): A pilot study
Annals of Oncology2018-12-0111 citations
Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol
BMJ Open2016-12-0187 citations